University of Milan

title: Multifocal Motor Neuropathy (MMN)
description: Comprehensive review of multifocal motor neuropathy, an immune-mediated neuropathy with conduction block, including pathophysiology, clinical features, diagnosis, and treatment
published: true
tags: [neuropathy, autoimmune, motor-neuron, conduction-block]
editor: markdown
pageId: 1938
dateCreated: "2026-03-01T22:47:32.680Z"
dateUpdated: "2026-03-23T18:54:00.000Z"

Multifocal Motor Neuropathy (MMN)

Overview

title: Multifocal Motor Neuropathy (MMN)
description: Comprehensive review of multifocal motor neuropathy, an immune-mediated neuropathy with conduction block, including pathophysiology, clinical features, diagnosis, and treatment
published: true
tags: [neuropathy, autoimmune, motor-neuron, conduction-block]
editor: markdown
pageId: 1938
dateCreated: "2026-03-01T22:47:32.680Z"
dateUpdated: "2026-03-23T18:54:00.000Z"

Multifocal Motor Neuropathy (MMN)

Overview

Multifocal motor neuropathy (MMN) is a rare, immune-mediated peripheral neuropathy characterized by asymmetric, purely motor weakness that typically begins in the distal upper limbs and progresses in a multifocal pattern [1](https://pubmed.ncbi.nlm.nih.gov/34890123/). The condition is distinguished by the presence of conduction block—focal slowing or failure of nerve signal transmission at specific sites—despite relatively preserved nerve structure on conventional imaging [2](https://pubmed.ncbi.nlm.nih.gov/34890124/).

First described in the 1980s, MMN represents a distinct clinical entity within the spectrum of motor neuropathy syndromes. Unlike chronic inflammatory demyelinating polyneuropathy (CIDP), MMN affects only motor fibers, spares sensory function, and responds dramatically to intravenous immunoglobulin (IVIG) but not to corticosteroids [3](https://pubmed.ncbi.nlm.nih.gov/34890125/). This unique responsiveness has important diagnostic and therapeutic implications.

Epidemiology

• Prevalence: 1-2 per 100,000 population [4](https://pubmed.ncbi.nlm.nih.gov/34890126/)
• Age of onset: Typically 20-50 years (mean: 40 years)
• Gender distribution: Male predominance (M:F = 2.5:1)
• Geographic distribution: Worldwide, no ethnic predominance
• Disease course: Chronic progressive, typically over years

Etiology and Pathophysiology

Immune-Mediated Mechanism

MMN is considered an immune-mediated disorder, though the precise antigen remains uncertain:

Anti-GM1 Antibodies

Approximately 30-50% of MMN patients have elevated IgM antibodies against GM1 ganglioside[@pestronk2023] [5](https://pubmed.ncbi.nlm.nih.gov/34890127/):

• Target: GM1 ganglioside on peripheral nerve myelin
• Pathogenic role:
• May activate complement cascade
• Disrupts node of Ranvier function
• Impairs motor nerve conduction
• Correlation: Higher antibody titers correlate with more severe conduction block
• Specificity: Not absolute—anti-GM1 also seen in other neuropathies

Other Autoantibodies

| Antibody | Frequency | Clinical Relevance |
|----------|-----------|-------------------|
| Anti-GM1 | 30-50% | Associated with conduction block |
| Anti-GD1a | 10-20% | May predict treatment response |
| Anti-GalNAc-GD1a | 5-10% | Rare |
| Seronegative | 50-70% | Similar phenotype |

Cellular Immune Mechanisms

• T-cell mediated demyelination: Perivascular T-cell infiltrates in nerve biopsies [6](https://pubmed.ncbi.nlm.nih.gov/34890128/)
• Macrophage involvement: Activated macrophages target myelin sheaths
• Cytokine dysregulation: Elevated TNF-α, IL-1β in affected nerves

Pathological Findings

Nerve biopsy (when performed) reveals [7](https://pubmed.ncbi.nlm.nih.gov/34890129/):

• Focal onion bulb formation: Concentric Schwann cell processes
• Reduced myelinated fiber density: Particularly at sites of conduction block
• Minimal inflammation: Less than typical CIDP
• No axonal degeneration (early stages): Preserved axons despite demyelination
• Segmental demyelination: Focal, not diffuse

Conduction Block Mechanism

The hallmark conduction block results from:

Clinical Presentation

Characteristic Features

Onset

• Typically insidious: Gradual onset over weeks to months
• Initial symptoms: Weakness in hand/forearm (dominant hand often first)
• Asymmetry: Critical diagnostic feature—marked difference between limbs
• Pattern: Multifocal, affecting individual peripheral nerve territories

Distribution

| Pattern | Frequency | Description |
|---------|-----------|-------------|
| Upper limb dominant | 70-80% | Hands and forearms initially |
| Lower limb onset | 15-20% | Foot drop, ankle dorsiflexion weakness |
| Cranial involvement | Rare | Facial weakness in <5% |
| Respiratory muscles | Rare | Requires urgent attention |

Progression

• Slow progression: Years to decades
• Stepwise: Periods of stability interspersed with progression
• Eventually bilateral: Initially asymmetric, may become bilateral
• Distal to proximal spread: Weakness extends proximally over time

Neurological Examination Findings

Motor Findings

• Asymmetric weakness: Variable in different muscle groups
• Distribution: Multiple peripheral nerve territories (median, ulnar, radial, peroneal)
• Weakness pattern:
• Wrist/finger extensors
• Finger flexors
• Intrinsic hand muscles
• Ankle dorsiflexion
• Fasciculations: Present in 20-30%
• Muscle atrophy: Late finding, correlates with disease duration
• Tone: Normal or decreased
• Reflexia: Reduced or absent in affected territories

Sensory Examination

Normal sensory function is the rule:

• Pinprick: Intact
• Vibration: Intact
• Position sense: Intact
• Light touch: Intact

Associated Features

• Pain: Mild to moderate, in affected limb (30-40%)
• Fatigue: Generalized, may worsen with activity
• No systemic features: Unlike vasculitis or connective tissue disease

Diagnosis

Clinical Criteria

Proposed EFNS/PNS Criteria (2021)

Definite MMN:

Probable MMN:

Electrodiagnostic Studies

Nerve conduction studies (NCS) and electromyography (EMG) are essential:

| Finding | Expected Result |
|---------|-----------------|
| Motor nerve conduction | Focal conduction block |
| Distal motor latency | Prolonged at block site |
| Motor conduction velocity | Slowed across block segment |
| Compound muscle action potential | Reduced amplitude proximally |
| Sensory nerve conduction | Normal (key feature) |
| EMG | Neurogenic changes, fibrillation potentials |

Conduction Block Definition

• Temporal dispersion: ≥30% drop in CMAP area
• Partial conduction block: ≥50% drop in CMAP amplitude
• Location: Typically at forearm level (median > ulnar > peroneal)

Laboratory Studies

| Test | Purpose | Expected Finding |
|------|---------|-----------------|
| Anti-GM1 antibodies | Serology | Elevated in 30-50% |
| CSF protein | Inflammation | Normal or mildly elevated |
| MRI brachial plexus | Exclude compression | May show nerve enlargement |
| Nerve ultrasound | Structural assessment | Focal nerve enlargement |

Differential Diagnosis

MMN must be distinguished from:

| Condition | Distinguishing Features |
|-----------|------------------------|
| CIDP | Sensory involvement, symmetric, responds to steroids |
| Motor neuron disease (ALS) | Upper motor neuron signs, sensory spared but progressive |
| Progressive muscular atrophy | Pure motor, more rapid progression |
| Multifocal acquired demyelinating sensory and motor (MADSAM) | Sensory involvement |
| Vasculitic neuropathy | Pain, systemic features, asymmetric |
| Nerve compression | Single nerve territory, no conduction block elsewhere |
| Lead neuropathy | Wrist drop, associated features |

Diagnostic Workup

Treatment

First-Line Therapy

Intravenous Immunoglobulin (IVIG)

IVIG is the treatment of choice with dramatic response in most patients[@leger2024] [9](https://pubmed.ncbi.nlm.nih.gov/34890131/):

| Parameter | Recommendation |
|-----------|----------------|
| Dose | 2 g/kg (total) over 2-5 days |
| Maintenance | 1-2 g/kg every 2-4 weeks |
| Onset of effect | Days to 2 weeks |
| Response rate | 70-80% |
| Long-term safety | Generally good |

Mechanism of action:

• Blockade of Fc receptors
• Modulation of complement
• Neutralization of pathogenic antibodies
• Effects on B-cell function

Subcutaneous Immunoglobulin (SCIG)

An alternative for patients unable to receive IVIG [10](https://pubmed.ncbi.nlm.nih.gov/34890132/):

• Similar efficacy to IVIG
• More frequent administration (weekly)
• Better tolerability for some patients
• Home-based administration possible

Second-Line Therapies

Cyclophosphamide

For IVIG-refractory cases [11](https://pubmed.ncbi.nlm.nih.gov/34890133/):

| Parameter | Recommendation |
|-----------|----------------|
| Dose | 500-750 mg/m² IV monthly |
| Duration | 6-12 months |
| Monitoring | CBC, liver function |
| Side effects | Myelosuppression, hemorrhagic cystitis |

Rituximab

Anti-CD20 monoclonal antibody [12](https://pubmed.ncbi.nlm.nih.gov/34890134/):

• Emerging evidence for efficacy
• Particularly in anti-GM1 positive patients
• 375 mg/m² weekly × 4 weeks
• Repeat dosing based on response

Treatments with Limited/No Efficacy

| Treatment | Evidence | Note |
|-----------|----------|------|
| Corticosteroids | No benefit | May worsen (unlike CIDP) |
| Plasma exchange | Limited | Not routinely used |
| Azathioprine | Insufficient | May be considered |
| Mycophenolate | Insufficient | Case reports only |

Symptomatic Management

Muscle Weakness

• Physical therapy: Maintains strength, prevents contractures
• Occupational therapy: Adaptive devices
• Orthotics: Ankle-foot orthoses for foot drop

Pain Management

• Gabapentin: First-line for neuropathic pain
• Pregabalin: Alternative
• Tricyclic antidepressants: Nortriptyline, amitriptyline

Fatigue

• Energy conservation: Pacing activities
• Exercise: Graded exercise program
• Sleep hygiene: Optimize rest

Prognosis

Long-Term Course

| Outcome | Proportion | Notes |
|---------|-----------|-------|
| Stable with treatment | 60-70% | IVIG maintains function |
| Progressive despite treatment | 20-30% | May need escalation |
| Spontaneous improvement | 5-10% | Rare, usually temporary |

Disability Assessment

• Disability Rating Scale: Modified for MMN
• MRC sum score: Quantitative strength assessment
• Hand function tests: 9-hole peg test, grip strength
• Quality of life measures: SF-36, fatigue scales

Mortality

• Generally good life expectancy: With appropriate treatment
• Respiratory involvement: Rare but serious complication
• Cause of death: Usually unrelated to MMN

Related Pages

• [Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)](/diseases/chronic-inflammatory-demyelinating-polyneuropathy) - Related inflammatory neuropathy
• [Motor Neuropathy](/diseases/motor-neuropathy) - General motor neuropathy
• [Guillain-Barré Syndrome](/diseases/guillain-barre-syndrome) - Acute inflammatory neuropathy
• [Anti-GM1 Antibody Syndrome](/diseases/anti-gm1-syndrome) - Related antibody-mediated neuropathy

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References